EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Current progress of anti‑PD‑1/PDL1 immunotherapy for glioblastoma (Review)

Jianheng Wu, Nannan Wang

Molecular Medicine Reports · 30.09.2024 · 30 (6)

DOI: 10.3892/mmr.2024.13344 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Medicine Reports, online erschienen am 30.09.2024. Verfasst von Jianheng Wu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Gaozhou People's Hospital, Gaozhou, Guangdong 525200, P.R. China. Hauptthemen laut MEDLINE: Glioblastoma, Immunotherapy, B7-H1 Antigen, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) is the most common central nervous system malignancy in adults. GBM may be classified as grade IV diffuse astrocytoma according to the 2021 World Health Organization revised classification of central nervous system tumors, which means it is the most aggressive, invasive, undifferentiated type of tumor. Immune checkpoint blockade (ICB), particularly anti‑programmed cell death protein‑1 (PD‑1)/PD‑1 ligand‑1 immunotherapy, has been confirmed to be successful across several tumor types. However, in GBM, this treatment is still uncommon and the efficacy is unpredictable, and

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaImmunotherapyB7-H1 AntigenImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorHumansBrain Neoplasms

Stichwörter der Autor:innen

PDL1PD‑1glioblastomaimmunotherapytumor microenvironment

Substanzen

B7-H1 AntigenImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorCD274 protein, humanPDCD1 protein, human

Autor:innen und Institutionen

  • Department of Neurosurgery, Gaozhou People's Hospital, Gaozhou, Guangdong 525200, P.R. China.
  • Department of Gastroenterology, Gaozhou People's Hospital, Gaozhou, Guangdong 525200, P.R. China.

Zitieren

APA

Wu, J., & Wang, N. (2024). Current progress of anti‑PD‑1/PDL1 immunotherapy for glioblastoma (Review). Molecular Medicine Reports, 30(6). https://doi.org/10.3892/mmr.2024.13344

Vancouver

Wu J, Wang N. Current progress of anti‑PD‑1/PDL1 immunotherapy for glioblastoma (Review). Molecular Medicine Reports. 2024;30(6). doi:10.3892/mmr.2024.13344

BibTeX
@article{Wu2024,
  author = {Wu, Jianheng and Wang, Nannan},
  title = {Current progress of anti‑PD‑1/PDL1 immunotherapy for glioblastoma (Review)},
  journal = {Molecular Medicine Reports},
  year = {2024},
  volume = {30},
  number = {6},
  doi = {10.3892/mmr.2024.13344}
}
Kostenlos starten →